202 related articles for article (PubMed ID: 31383722)
1. Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition.
Dhir T; Schultz CW; Jain A; Brown SZ; Haber A; Goetz A; Xi C; Su GH; Xu L; Posey J; Jiang W; Yeo CJ; Golan T; Pishvaian MJ; Brody JR
Mol Cancer Res; 2019 Oct; 17(10):2029-2041. PubMed ID: 31383722
[TBL] [Abstract][Full Text] [Related]
2. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
3. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
4. Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling.
Dowless M; Lowery CD; Shackleford T; Renschler M; Stephens J; Flack R; Blosser W; Gupta S; Stewart J; Webster Y; Dempsey J; VanWye AB; Ebert P; Iversen P; Olsen JB; Gong X; Buchanan S; Houghton P; Stancato L
Clin Cancer Res; 2018 Dec; 24(23):6028-6039. PubMed ID: 30131386
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological Effects of CDK4 & 6 Selective Inhibitor Abemaciclib in Hormone Receptor-Positive Breast Cancer].
Tamaki C; Hayashi S; Sato A; Maeda K; Sakaguchi S; Buchanan S; Enatsu S
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1405-1411. PubMed ID: 31530780
[TBL] [Abstract][Full Text] [Related]
6. Posttranscriptional Regulation of
Chand SN; Zarei M; Schiewer MJ; Kamath AR; Romeo C; Lal S; Cozzitorto JA; Nevler A; Scolaro L; Londin E; Jiang W; Meisner-Kober N; Pishvaian MJ; Knudsen KE; Yeo CJ; Pascal JM; Winter JM; Brody JR
Cancer Res; 2017 Sep; 77(18):5011-5025. PubMed ID: 28687616
[TBL] [Abstract][Full Text] [Related]
7. Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6-Cyclin D-Rb pathway.
Wang D; Bao H
Cancer Chemother Pharmacol; 2022 Jan; 89(1):31-40. PubMed ID: 34655298
[TBL] [Abstract][Full Text] [Related]
8. Abemaciclib sensitizes HPV-negative cervical cancer to chemotherapy via specifically suppressing CDK4/6-Rb-E2F and mTOR pathways.
Liu Y; Zhao R; Fang S; Li Q; Jin Y; Liu B
Fundam Clin Pharmacol; 2021 Feb; 35(1):156-164. PubMed ID: 32446293
[TBL] [Abstract][Full Text] [Related]
9. The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma.
Brown SZ; McCarthy GA; Carroll JR; Di Niro R; Pelz C; Jain A; Sutton TL; Holly HD; Nevler A; Schultz CW; McCoy MD; Cozzitorto JA; Jiang W; Yeo CJ; Dixon DA; Sears RC; Brody JR
Mol Cell Biol; 2022 Jul; 42(7):e0001822. PubMed ID: 35703534
[TBL] [Abstract][Full Text] [Related]
10. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
11. p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer.
Bae HJ; Kang SK; Kwon WS; Jeong I; Park S; Kim TS; Kim KH; Kim H; Jeong HC; Chung HC; Rha SY
Biochem Pharmacol; 2021 Jan; 183():114320. PubMed ID: 33161023
[TBL] [Abstract][Full Text] [Related]
12. Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells.
Zarei M; Lal S; Parker SJ; Nevler A; Vaziri-Gohar A; Dukleska K; Mambelli-Lisboa NC; Moffat C; Blanco FF; Chand SN; Jimbo M; Cozzitorto JA; Jiang W; Yeo CJ; Londin ER; Seifert EL; Metallo CM; Brody JR; Winter JM
Cancer Res; 2017 Aug; 77(16):4460-4471. PubMed ID: 28652247
[TBL] [Abstract][Full Text] [Related]
13. Human antigen R mediated post-transcriptional regulation of inhibitors of apoptosis proteins in pancreatic cancer.
Lukosiute-Urboniene A; Jasukaitiene A; Silkuniene G; Barauskas V; Gulbinas A; Dambrauskas Z
World J Gastroenterol; 2019 Jan; 25(2):205-219. PubMed ID: 30670910
[TBL] [Abstract][Full Text] [Related]
14. Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non-Small Cell Lung Cancer
Naz S; Sowers A; Choudhuri R; Wissler M; Gamson J; Mathias A; Cook JA; Mitchell JB
Clin Cancer Res; 2018 Aug; 24(16):3994-4005. PubMed ID: 29716919
[No Abstract] [Full Text] [Related]
15. Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer.
O'Brien N; Conklin D; Beckmann R; Luo T; Chau K; Thomas J; Mc Nulty A; Marchal C; Kalous O; von Euw E; Hurvitz S; Mockbee C; Slamon DJ
Mol Cancer Ther; 2018 May; 17(5):897-907. PubMed ID: 29483214
[TBL] [Abstract][Full Text] [Related]
16. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
17. Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells.
Wu Y; Zheng Q; Li Y; Wang G; Gao S; Zhang X; Yan X; Zhang X; Xie J; Wang Y; Sun X; Meng X; Yin B; Wang B
J Exp Clin Cancer Res; 2019 Aug; 38(1):376. PubMed ID: 31455378
[TBL] [Abstract][Full Text] [Related]
18. CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype.
Lal S; Cheung EC; Zarei M; Preet R; Chand SN; Mambelli-Lisboa NC; Romeo C; Stout MC; Londin E; Goetz A; Lowder CY; Nevler A; Yeo CJ; Campbell PM; Winter JM; Dixon DA; Brody JR
Mol Cancer Res; 2017 Jun; 15(6):696-707. PubMed ID: 28242812
[TBL] [Abstract][Full Text] [Related]
19. Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells.
Jimbo M; Blanco FF; Huang YH; Telonis AG; Screnci BA; Cosma GL; Alexeev V; Gonye GE; Yeo CJ; Sawicki JA; Winter JM; Brody JR
Oncotarget; 2015 Sep; 6(29):27312-31. PubMed ID: 26314962
[TBL] [Abstract][Full Text] [Related]
20. BAG3 regulates stability of IL-8 mRNA via interplay between HuR and miR-4312 in PDACs.
Li C; Jiang JY; Wang JM; Sun J; An MX; Li S; Yan J; Wang HQ
Cell Death Dis; 2018 Aug; 9(9):863. PubMed ID: 30154469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
